Evidence map›Paper›PMID 31801562›Full record

ArticleMalaria journal2019

Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether-lumefantrine or dihydroartemisinin-piperaquine treatment.

Protus Omondi, Marion Burugu, Damaris Matoke-Muhia, Edwin Too, Eva A Nambati, William Chege, Kelvin B Musyoka, Kelvin Thiongo, Maureen Otinga, Francis Muregi and 1 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Prevalence of asymptomaticWellcome open research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Protus OmondiDepartment of Biochemistry, Microbiology, and Biotechnology, Kenyatta University, P.O Box 43884-00100, Nairobi, Kenya.
Marion BuruguDepartment of Biochemistry, Microbiology, and Biotechnology, Kenyatta University, P.O Box 43884-00100, Nairobi, Kenya.
Damaris Matoke-MuhiaCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya.
Edwin TooCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya.
Eva A NambatiCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya.
William ChegeCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya.
Kelvin B MusyokaDepartment of Biochemistry, Jomo Kenyatta University of Agriculture and Technology, P.O Box 62000-00200, Nairobi, Kenya.
Kelvin ThiongoCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya.
Maureen OtingaCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya.
Francis MuregiDepartment of Biological Sciences, Mount Kenya University, P.O Box 342-00100, Nairobi, Kenya.
Francis KimaniCentre for Biotechnology Research and Development, Kenya Medical Research Institute, P.O Box 54840-00200, Nairobi, Kenya. kimanift@yahoo.com.ORCID http://orcid.org/0000-0001-5150-2068
Kenya Medical Research Institute · KEKenyatta University · KEJomo Kenyatta University of Agriculture and Technology · KEMount Kenya University · KE

Funding

Government of the Republic of Kenya IRG SERU 3236
6 · The paper itself

Abstract

backgroundThe efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) against asexual parasites population has been documented. However, the effect of these anti-malarials on sexual parasites is still less clear. Gametocyte clearance following treatment is essential for malaria control and elimination efforts; therefore, the study sought to determine trends in gametocyte clearance after AL or DP treatment in children from a malaria-endemic site in Kenya.

methodsChildren aged between 0.5 and 12 years from Busia, western Kenya with uncomplicated Plasmodium falciparum malaria were assigned randomly to AL or DP treatment. A total of 334 children were enrolled, and dried blood spot samples were collected for up to 6 weeks after treatment during the peak malaria transmission season in 2016 and preserved. Plasmodium falciparum gametocytes were detected by qRT-PCR and gametocyte prevalence, density and mean duration of gametocyte carriage were determined.

resultsAt baseline, all the 334 children had positive asexual parasites by microscopy, 12% (40/334) had detectable gametocyte by microscopy, and 83.7% (253/302) children had gametocytes by RT-qPCR. Gametocyte prevalence by RT-qPCR decreased from 85.1% (126/148) at day 0 to 7.04% (5/71) at day 42 in AL group and from 82.4% (127/154) at day 0 to 14.5% (11/74) at day 42 in DP group. The average duration of gametocyte carriage as estimated by qRT-PCR was slightly shorter in the AL group (4.5 days) than in the DP group (5.1 days) but not significantly different (p = 0.301).

conclusionThe study identifies no significant difference between AL and DP in gametocyte clearance. Gametocytes persisted up to 42 days post treatment in minority of individuals in both treatment arms. A gametocytocidal drug, in combination with artemisinin-based combination therapy, will be useful in blocking malaria transmission more efficiently.

Indexed as

AntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsChildChild, PreschoolFemaleHumansInfantKenyaMalaria, FalciparumMalePiperazinesPlasmodium falciparumPrevalenceQuinolinesAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsartenimolpiperaquinePiperazinesQuinolinesArtemether–lumefantrineDihydroartemisinin/piperaquinePlasmodium falciparum gametocyte

Identifiers

PMID31801562
PMCPMC6891957
OpenAlexW2992353016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.